[{"from": "human", "value": "Could you give me a brief overview of this molecule? [C][N][C][C@H1][C][=C][Branch1][=Branch1][C][C][O][Ring1][=Branch1][C][=C][S][Ring1][Branch2]"}, {"from": "gpt", "value": "The molecule is a novel psychotropic drug being investigated for the treatment of schizophrenia.  Unlike other drugs used for this condition, SEP-363856 does not bind to the dopamine D2 receptors, but exerts actions on the trace amine\u2013associated receptor 1 (TAAR1) and 5-hydroxytryptamine type 1A (5-HT1A).   SEP-363856 was developed by Sunovion pharmaceuticals. An initial clinical study has shown this drug may be effective against both positive and negative symptoms of schizophrenia. Negative symptoms of schizophrenia are more difficult to treat and may include flattened affect, anhedonia,  and social withdrawal. Additional clinical trials of SEP-363856 are required to confirm the safety and efficacy of this drug."}]